Opt-in ethnicity database speeds recruitment in Phase III trial, says Acurian

- Last updated on GMT

Related tags: Clinical trial, Contract research organization

Acurian says that, increasingly, pharmaceutical industry sponsors want greater ethnic diversity among trial populations in clinical research.

The US patient recruitment specialist made the suggestion following the launch of an opt-in patient database which, it claims, enables sponsors and contract research organisations (CRO) to access ethnically-diverse populations.

Acurian said that despite the misperception that minorities are reticent about trial participation it has built up a database of 5.7 million African Americans, 10.3 million people of Hispanic/Latino descent, and 2.5 million people of Asian descent.

The firm went on to cite the utility of such data, explaining it used the database to recruit 240 African Americans participants for a Phase III study of a hypertension drug four months quicker than the anticipated in-patient recruitment deadline.

Scott Connor, company VP of marketing, added that: “Our customers are eager to enroll minorities to ensure their trials represent diverse demographics.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more